Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.74 |
| ▸ | STAT3 | P40763 | 1/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.74 |
| ▸ | RELA | Q04206 | 1/20 | 0.74 |
| ▸ | JUN | P05412 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744663 | 1.00 | NFKB1 (0.74) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2744728 | 0.95 | NFKB1 (0.76) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2744733 | 0.95 | NFKB1 (0.76) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL30493821 | 0.92 | NFKB1 (0.79) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2743877 | 0.92 | NFKB1 (0.79) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2743876 | 0.92 | NFKB1 (0.79) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL27974543 | 0.91 | TUBB1 (0.77) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2744234 | 0.91 | CYP2D6 (0.91) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL2744233 | 0.91 | CYP2D6 (0.91) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 | |
| SCHEMBL27974391 | 0.90 | BACE1 (0.80) | NFKB1NFE2L2CYP1A2ALOX5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | NFKB1 328/4885NFE2L2 109/4885CYP1A2 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.